Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01423630|
Recruitment Status : Active, not recruiting
First Posted : August 26, 2011
Last Update Posted : October 19, 2017
Probiotics and fruit fibre are given for 12 weeks to patients with fatty liver disease.
The hypothesis is that probiotic bacteria and fruit fibre affect the gut microbial composition in a positive manner. The improved ecological system is believed to contribute to improved liver health and thereby counteract fatty liver disease.
|Condition or disease||Intervention/treatment||Phase|
|Fatty Liver||Dietary Supplement: Probiotics and fruit fibre||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver|
|Actual Study Start Date :||August 2011|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
Experimental: Probiotics and fruit fibre
Probiotics and fruit fibre
Dietary Supplement: Probiotics and fruit fibre
probiotics and fruit fibre
- Improved and normalized liver status [ Time Frame: after 12 weeks intervention ]normalized concentrations of liver enzymes in plasma. Magnetic resonanse imaging (compared to magnetic resonanse imaging before intervention) will also be used in the investigation of improved liver status.
- Changes in the gut bacterial flora [ Time Frame: after 12 weeks intervention ]Changes and differences of the gut bacterial flora will be addressed in detail, e.g. changes in concentration of specific bacterial groups (e.g. Lactobacillus) before and after the intervention period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01423630
|Skåne University Hospital|